Treatment of enterotoxigenic and enteropathogenic Escherichia coli-induced diarrhoea in children with bovine immunoglobulin milk concentrate from hyperimmunized cows: A double-blind, placebo-controlled, clinical trial

T. H. Casswall, S. A. Sarker, S. M. Faruque, A. Weintraub, M. J. Albert, G. J. Fuchs, N. H. Alam, A. K. Dahlstrom, H. Link, H. Brussow, L. Hammarstrom

Research output: Contribution to journalArticlepeer-review

36 Scopus citations

Abstract

Background: Enterotoxigenic Escherichia coli (ETEC) and enteropathogenic Escherichia coli (EPEC) are important causes of diarrhoea in young children and are associated with significant mortality rates. Passive immunization with antibodies from immunized cows has previously been shown to be effective as prophylaxis against E. coli-induced diarrhoea and therapeutically against rotavirus and cryptosporidia-induced diarrhoea. Methods: We tested the therapeutic efficacy of an oral bovine immunoglobulin milk concentrate (BIC) from cows hyperimmunized with ETEC and EPEC strains, in a randomized, placebo-controlled study in children with E. coli-induced diarrhoea. Eighty-six children between 4-24 months of age attending the International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR, B) with E. coli-induced diarrhoea (63 EPEC/ETEC and 23 with other diarrhoeagenic E. coli) were randomly assigned to receive orally administered BIC (20 g) containing anti-ETEC/EPEC antibodies or a placebo preparation daily for 4 consecutive days. Daily stool output, intake of oral rehydration solution (ORS), stool frequency, and presence of diarrhoeagenic E. coli strains in the stool were monitored for 4 days. Results: Children in the treatment group tolerated the BIC with no side effects. There were no significant differences between the two groups with regard to ORS intake, stool output, frequency of diarrhoea, or clearance of pathogen. Nor was there any significant alteration in the duration of diarrhoea. Conclusions: In contrast to the prophylactic efficacy of anti-E. coli BIC and the therapeutic efficacy of a similarly prepared anti-rotavirus BIC, antibodies from hyperimmunized cows appear to have no significant therapeutic benefit in the treatment of acute diarrhoea due to EPEC/ETEC.

Original languageEnglish
Pages (from-to)711-718
Number of pages8
JournalScandinavian Journal of Gastroenterology
Volume35
Issue number7
DOIs
StatePublished - 2000

Bibliographical note

Funding Information:
This study was supported by the International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR, B); The Swedish International Development Agency (SIDA), Karo-linska Institutet, Stockholm, Sweden, and the Ruth and Richards Julin Foundation, Stockholm, Sweden. We are indebted to Ms. L. Unicomb for laboratory support, and also thank Drs. Aminul Islam and Shaila Sharmin, Ms. Afia Begum, Afroza Begum and the nurses of the Clinical Study Ward of the Clinical Research and Service Centre of ICDDR, B for their work.

Keywords

  • Bovine antibodies
  • Diarrhoea
  • Enteropathogenic Escherichia coli
  • Enterotoxigenic Escherichia coli
  • Escherichia coli
  • Infants and children
  • Oral therapy

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint

Dive into the research topics of 'Treatment of enterotoxigenic and enteropathogenic Escherichia coli-induced diarrhoea in children with bovine immunoglobulin milk concentrate from hyperimmunized cows: A double-blind, placebo-controlled, clinical trial'. Together they form a unique fingerprint.

Cite this